BRCA1 and ovarian cancer: While loss of BRCA1 promoter methylation during therapy has been described in ovarian cancer [41], notably, such loss of methylation may not explain therapy resistance in the TNT trial since methylation status was determined in samples collected at trial inclusion [7].